We observed a variable IgA and IgG response to the P17 peptide, with the majority of individuals (87% and 81% for IgA and IgG, respectively) not showing stronger antibody binding than malaria-naïve U.S. individuals (Fig. 3I). This evidence concerns the gene CD79A and malaria.